Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis.

Al-Aloul M, Nazareth D, Walshaw M.

Clin Kidney J. 2019 Feb 7;12(5):652-658. doi: 10.1093/ckj/sfz005. eCollection 2019 Oct.

2.

Loss of incretin effect contributes to postprandial hyperglycaemia in cystic fibrosis-related diabetes.

Frost F, Jones GH, Dyce P, Jackson V, Nazareth D, Walshaw MJ.

Diabet Med. 2019 Aug 29. doi: 10.1111/dme.14121. [Epub ahead of print]

PMID:
31466128
3.

Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens: A Cohort Study Using National Registry Data.

Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ.

Ann Am Thorac Soc. 2019 Jul 19. doi: 10.1513/AnnalsATS.201902-122OC. [Epub ahead of print]

PMID:
31319678
4.

Experiences of overseas nurse educators teaching in New Zealand.

Skaria R, Whitehead D, Leach L, Walshaw M.

Nurse Educ Today. 2019 Oct;81:7-12. doi: 10.1016/j.nedt.2019.05.032. Epub 2019 May 22.

PMID:
31295662
5.

Cystic fibrosis-related diabetes: optimizing care with a multidisciplinary approach.

Frost F, Dyce P, Ochota A, Pandya S, Clarke T, Walshaw MJ, Nazareth DS.

Diabetes Metab Syndr Obes. 2019 Apr 26;12:545-552. doi: 10.2147/DMSO.S180597. eCollection 2019.

6.

Cystic fibrosis: Diagnosis and management - NICE guideline 78.

Walshaw MJ.

Paediatr Respir Rev. 2019 Aug;31:12-14. doi: 10.1016/j.prrv.2019.02.006. Epub 2019 Feb 28. Review.

PMID:
30962150
7.

Evaluation of Gastric Emptying in Cystic Fibrosis Using Bedside Ultrasonography.

Nazareth D, Mohan K, Fewins H, Walshaw M.

J Ultrasound Med. 2019 Mar 28. doi: 10.1002/jum.15001. [Epub ahead of print]

PMID:
30924192
8.

Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from the UK CF Registry.

Frost F, Nazareth D, Shaw M, Walshaw MJ.

J Cyst Fibros. 2019 Mar;18(2):294-298. doi: 10.1016/j.jcf.2018.10.011. Epub 2018 Oct 25.

PMID:
30741162
9.

Between a Rock and an Airspace: Pneumothorax After Extracorporeal Shock Wave Lithotripsy for Renal Stones in a Patient With Cystic Fibrosis.

Frost F, Griffiths P, Brockelsby C, Lynch C, Walshaw MJ, Nazareth D.

Chest. 2018 Sep;154(3):e61-e63. doi: 10.1016/j.chest.2018.03.023.

PMID:
30195371
10.

Pulmonary function testing is safe in patients with thoracic aortic aneurysms.

Frost F, Peat R, McWean J, Shaw M, Field M, Nazareth D, Walshaw M.

Eur Respir J. 2018 Nov 15;52(5). pii: 1800928. doi: 10.1183/13993003.00928-2018. Print 2018 Nov. No abstract available.

PMID:
30190275
11.

Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes.

Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ.

J Cyst Fibros. 2018 Nov;17(6):798-803. doi: 10.1016/j.jcf.2018.05.005. Epub 2018 Jun 7.

PMID:
29885744
12.

Case Report: Haemolytic anaemia with ceftazidime use in a patient with cystic fibrosis.

Yong J, Frost F, Nazareth D, Walshaw M.

F1000Res. 2018 Apr 18;7:475. doi: 10.12688/f1000research.14505.1. eCollection 2018.

13.

Re: Radiology-led lung escalation pathway: a streamlined innovative service expediting the diagnosis of lung cancer.

Nanapragasam A, Ledson M, Walshaw M.

Clin Radiol. 2018 Jul;73(7):673. doi: 10.1016/j.crad.2018.02.020. Epub 2018 Apr 5. No abstract available.

PMID:
29628117
14.

Transmission and lineage displacement drive rapid population genomic flux in cystic fibrosis airway infections of a Pseudomonas aeruginosa epidemic strain.

Williams D, Fothergill JL, Evans B, Caples J, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S.

Microb Genom. 2018 Mar;4(3). doi: 10.1099/mgen.0.000167. Epub 2018 Mar 16.

15.

Ghost of chest drain past.

Frost F, Hare J, Holemans J, Walshaw M.

Thorax. 2018 Jun;73(6):595-596. doi: 10.1136/thoraxjnl-2017-210991. Epub 2017 Nov 29. No abstract available.

PMID:
29187593
16.

Diagnosis and management of cystic fibrosis: summary of NICE guidance.

Villanueva G, Marceniuk G, Murphy MS, Walshaw M, Cosulich R; Guideline Committee.

BMJ. 2017 Oct 26;359:j4574. doi: 10.1136/bmj.j4574. Review. No abstract available.

PMID:
29074599
17.

Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung.

Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, Walshaw MJ, Williams D, Fothergill JL, De Soyza A, Winstanley C.

Eur Respir J. 2017 Apr 26;49(4). pii: 1602108. doi: 10.1183/13993003.02108-2016. Print 2017 Apr.

18.

Evidence summary: the relationship between oral health and pulmonary disease.

Manger D, Walshaw M, Fitzgerald R, Doughty J, Wanyonyi KL, White S, Gallagher JE.

Br Dent J. 2017 Apr 7;222(7):527-533. doi: 10.1038/sj.bdj.2017.315. Review.

PMID:
28387268
19.

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler IC, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O'Brien C, O'Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA.

Science. 2016 Nov 11;354(6313):751-757. doi: 10.1126/science.aaf8156.

20.

Potential impact on fertility of new systemic therapies for cystic fibrosis.

Jones GH, Walshaw MJ.

Paediatr Respir Rev. 2015 Oct;16 Suppl 1:25-7. doi: 10.1016/j.prrv.2015.07.013. Epub 2015 Sep 26. Review.

PMID:
26410278
21.

Divergent, coexisting Pseudomonas aeruginosa lineages in chronic cystic fibrosis lung infections.

Williams D, Evans B, Haldenby S, Walshaw MJ, Brockhurst MA, Winstanley C, Paterson S.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):775-85. doi: 10.1164/rccm.201409-1646OC.

22.

Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections.

James CE, Davies EV, Fothergill JL, Walshaw MJ, Beale CM, Brockhurst MA, Winstanley C.

ISME J. 2015 Jun;9(6):1391-8. doi: 10.1038/ismej.2014.223. Epub 2014 Dec 2.

23.

Highlights of the North American CF Conference 2013.

Walshaw M.

Paediatr Respir Rev. 2014 Jun;15 Suppl 1:8-9. doi: 10.1016/j.prrv.2014.04.005. Epub 2014 Apr 13.

PMID:
24821547
24.

The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.

Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, Brownlee K.

Pharmacoeconomics. 2014 Feb;32(2):159-72. doi: 10.1007/s40273-013-0122-x.

PMID:
24338264
25.

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis.

Uttley L, Harnan S, Cantrell A, Taylor C, Walshaw M, Brownlee K, Tappenden P.

Eur Respir Rev. 2013 Dec;22(130):476-86. doi: 10.1183/09059180.00001513. Review.

26.

Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.

Al-Aloul M, Nazareth D, Walshaw M.

J Aerosol Med Pulm Drug Deliv. 2014 Aug;27(4):299-305. doi: 10.1089/jamp.2013.1055. Epub 2013 Nov 12.

PMID:
24219814
27.

Coming of age in cystic fibrosis - transition from paediatric to adult care.

Nazareth D, Walshaw M.

Clin Med (Lond). 2013 Oct;13(5):482-6. doi: 10.7861/clinmedicine.13-5-482. Review.

28.

A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material.

Bediaga NG, Davies MP, Acha-Sagredo A, Hyde R, Raji OY, Page R, Walshaw M, Gosney J, Alfirevic A, Field JK, Liloglou T.

Br J Cancer. 2013 Oct 29;109(9):2404-11. doi: 10.1038/bjc.2013.623. Epub 2013 Oct 10.

29.

Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients.

Fothergill JL, Ledson MJ, Walshaw MJ, McNamara PS, Southern KW, Winstanley C.

J Cyst Fibros. 2013 Dec;12(6):675-81. doi: 10.1016/j.jcf.2013.04.007. Epub 2013 May 29.

30.

Extensive diversification is a common feature of Pseudomonas aeruginosa populations during respiratory infections in cystic fibrosis.

Ashish A, Paterson S, Mowat E, Fothergill JL, Walshaw MJ, Winstanley C.

J Cyst Fibros. 2013 Dec;12(6):790-3. doi: 10.1016/j.jcf.2013.04.003. Epub 2013 May 1.

31.

A review of renal disease in cystic fibrosis.

Nazareth D, Walshaw M.

J Cyst Fibros. 2013 Jul;12(4):309-17. doi: 10.1016/j.jcf.2013.03.005. Epub 2013 Apr 22. Review.

32.

Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study.

Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ.

JRSM Short Rep. 2013 Jan;4(1):1. doi: 10.1258/shorts.2012.012018. Epub 2013 Jan 14.

33.

Abdominal trauma and lung nodules.

Nazareth D, Seshadri N, Binukrishnan S, Ledson M, Walshaw M, Mohan K.

Postgrad Med J. 2013 Jun;89(1052):366. doi: 10.1136/postgradmedj-2012-131359. Epub 2013 Jan 15. No abstract available.

PMID:
23322745
34.

Informed conditioning on clinical covariates increases power in case-control association studies.

Zaitlen N, Lindström S, Pasaniuc B, Cornelis M, Genovese G, Pollack S, Barton A, Bickeböller H, Bowden DW, Eyre S, Freedman BI, Friedman DJ, Field JK, Groop L, Haugen A, Heinrich J, Henderson BE, Hicks PJ, Hocking LJ, Kolonel LN, Landi MT, Langefeld CD, Le Marchand L, Meister M, Morgan AW, Raji OY, Risch A, Rosenberger A, Scherf D, Steer S, Walshaw M, Waters KM, Wilson AG, Wordsworth P, Zienolddiny S, Tchetgen ET, Haiman C, Hunter DJ, Plenge RM, Worthington J, Christiani DC, Schaumberg DA, Chasman DI, Altshuler D, Voight B, Kraft P, Patterson N, Price AL.

PLoS Genet. 2012;8(11):e1003032. doi: 10.1371/journal.pgen.1003032. Epub 2012 Nov 8.

35.

Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice.

Bolton CE, Bush A, Hurst JR, Kotecha S, McGarvey L, Stocks J, Walshaw MJ.

Thorax. 2012 Dec;67(12):1110. doi: 10.1136/thoraxjnl-2012-202637. Epub 2012 Sep 19.

PMID:
22993167
36.

DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer.

Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, Walshaw M, Sheard J, Field JK, Liloglou T.

Cancer Res. 2012 Nov 15;72(22):5692-701. doi: 10.1158/0008-5472.CAN-12-2309. Epub 2012 Sep 7.

37.

Fracture and intra-cardiac embolisation of a totally implantable vascular access device.

Nazareth D, Stables R, Ledson M, Walshaw M, Greenwood J.

Respiration. 2012;83(6):553. doi: 10.1159/000337255. Epub 2012 Apr 20. No abstract available.

38.

Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study.

Ashish A, Shaw M, McShane J, Ledson MJ, Walshaw MJ.

JRSM Short Rep. 2012 Feb;3(2):12. doi: 10.1258/shorts.2011.011119. Epub 2012 Feb 27.

39.

Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections.

Fothergill JL, Walshaw MJ, Winstanley C.

Eur Respir J. 2012 Jul;40(1):227-38. doi: 10.1183/09031936.00204411. Epub 2012 Feb 9.

40.

Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing non-emergent coronary artery bypass grafting.

Saleh HZ, Mohan K, Shaw M, Al-Rawi O, Elsayed H, Walshaw M, Chalmers JA, Fabri BM.

Eur J Cardiothorac Surg. 2012 Jul;42(1):108-13; discussion 113. doi: 10.1093/ejcts/ezr271. Epub 2012 Jan 22.

PMID:
22290913
41.

Increasing resistance of the Liverpool Epidemic Strain (LES) of Pseudomonas aeruginosa (Psa) to antibiotics in cystic fibrosis (CF)--a cause for concern?

Ashish A, Shaw M, Winstanley C, Ledson MJ, Walshaw MJ.

J Cyst Fibros. 2012 May;11(3):173-9. doi: 10.1016/j.jcf.2011.11.004. Epub 2011 Dec 5.

42.

Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates.

Dietrich D, Kneip C, Raji O, Liloglou T, Seegebarth A, Schlegel T, Flemming N, Rausch S, Distler J, Fleischhacker M, Schmidt B, Giles T, Walshaw M, Warburton C, Liebenberg V, Field JK.

Int J Oncol. 2012 Mar;40(3):825-32. doi: 10.3892/ijo.2011.1264. Epub 2011 Nov 16.

PMID:
22108652
43.

Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections.

Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA, Winstanley C.

Am J Respir Crit Care Med. 2011 Jun 15;183(12):1674-9. doi: 10.1164/rccm.201009-1430OC. Epub 2011 Feb 4.

PMID:
21297072
44.

SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates.

Schmidt B, Liebenberg V, Dietrich D, Schlegel T, Kneip C, Seegebarth A, Flemming N, Seemann S, Distler J, Lewin J, Tetzner R, Weickmann S, Wille U, Liloglou T, Raji O, Walshaw M, Fleischhacker M, Witt C, Field JK.

BMC Cancer. 2010 Nov 3;10:600. doi: 10.1186/1471-2407-10-600.

45.

Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Fothergill JL, Mowat E, Walshaw MJ, Ledson MJ, James CE, Winstanley C.

Antimicrob Agents Chemother. 2011 Jan;55(1):426-8. doi: 10.1128/AAC.01257-10. Epub 2010 Oct 25.

46.

A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection.

Carter ME, Fothergill JL, Walshaw MJ, Rajakumar K, Kadioglu A, Winstanley C.

J Infect Dis. 2010 Sep 15;202(6):935-42. doi: 10.1086/655781.

PMID:
20704484
47.

Self-care and cystic fibrosis: a review of research with adults.

Greenop D, Glenn S, Ledson M, Walshaw M.

Health Soc Care Community. 2010 Nov;18(6):653-61. doi: 10.1111/j.1365-2524.2010.00939.x. Review.

PMID:
20584088
48.

Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections.

Fothergill JL, White J, Foweraker JE, Walshaw MJ, Ledson MJ, Mahenthiralingam E, Winstanley C.

J Clin Microbiol. 2010 Jun;48(6):2053-9. doi: 10.1128/JCM.00019-10. Epub 2010 Apr 21.

49.

Empyema due to a highly transmissible Pseudomonas aeruginosa strain in an adult cystic fibrosis patient.

Mohan K, Lakshman V, Fothergill JL, Ledson MJ, Winstanley C, Walshaw MJ.

J Med Microbiol. 2010 May;59(Pt 5):614-6. doi: 10.1099/jmm.0.014696-0. Epub 2010 Feb 4.

PMID:
20133415
50.

Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, Winstanley C.

J Med Microbiol. 2010 Apr;59(Pt 4):472-81. doi: 10.1099/jmm.0.015875-0. Epub 2009 Dec 17.

PMID:
20019149

Supplemental Content

Loading ...
Support Center